Login to Your Account



Ablynx, B-I Sign $265M Deal To Use Nanobodies in Alzheimer's

By Peter O'Donnell


Wednesday, January 10, 2007
BRUSSELS, Belgium - Boehringer Ingelheim and Ablynx have come together on a $265 million deal to explore the use of Ablynx' novel class of therapeutic proteins - nanobodies - in treatments for Alzheimer's disease. Andreas Barner, Boehringer Ingelheim's vice chairman and head of pharma research, described it as a "powerful and unique technology." (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription